ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 114 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2015. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $7,233,000 | -33.4% | 100,000 | -39.4% | 4.76% | -32.7% |
| Q4 2017 | $10,864,000 | -27.7% | 165,000 | -45.0% | 7.08% | +70.6% |
| Q3 2017 | $15,036,000 | +224.9% | 300,000 | +200.0% | 4.15% | +58.5% |
| Q2 2017 | $4,628,000 | +74.8% | 100,000 | +33.3% | 2.62% | +99.7% |
| Q1 2017 | $2,648,000 | +139.0% | 75,000 | -6.2% | 1.31% | +561.6% |
| Q3 2016 | $1,108,000 | -6.1% | 80,000 | +60.0% | 0.20% | -57.3% |
| Q3 2015 | $1,180,000 | -90.4% | 50,000 | -66.7% | 0.46% | -88.0% |
| Q2 2015 | $12,264,000 | -33.8% | 150,000 | -25.0% | 3.87% | -50.3% |
| Q1 2015 | $18,520,000 | +129.0% | 200,000 | 0.0% | 7.79% | +99.3% |
| Q4 2014 | $8,088,000 | +164.5% | 200,000 | +60.0% | 3.91% | +139.4% |
| Q3 2014 | $3,058,000 | +54.4% | 125,000 | 0.0% | 1.63% | +76.7% |
| Q2 2014 | $1,980,000 | -3.0% | 125,000 | -7.4% | 0.92% | -2.1% |
| Q1 2014 | $2,041,000 | -1.0% | 135,000 | -10.0% | 0.94% | -19.7% |
| Q4 2013 | $2,061,000 | – | 150,000 | – | 1.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,629,835 | $116,685,000 | 25.08% |
| Aviva Holdings Ltd. | 1,200,100 | $53,248,000 | 14.21% |
| Boxer Capital, LLC | 1,375,000 | $61,009,000 | 6.77% |
| BB BIOTECH AG | 3,282,964 | $145,665,000 | 3.86% |
| Rhenman & Partners Asset Management AB | 353,961 | $15,705,000 | 1.57% |
| PFM Health Sciences, LP | 1,970,134 | $87,415,000 | 1.28% |
| Bellevue Group AG | 391,852 | $17,386,000 | 1.10% |
| Pentwater Capital Management LP | 2,351,500 | $104,336,000 | 0.88% |
| Partner Investment Management, L.P. | 25,440 | $1,129,000 | 0.86% |
| SABBY MANAGEMENT, LLC | 100,369 | $4,453,000 | 0.57% |